In the multivariate analysis, the absence of high blood pressure, a greater number of preventive treatments at the start, and a lower number of migraine days/month after anti‐CGRP treatment were independently associated with withdrawal of the treatment (p < 0.05). Here, CALCA is linked to hypertensive disorder.